By Adam Bonislawski
Biodesix said this week that it is collaborating with pharma firm Kadmon on a 620-patient Phase III clinical trial of that company's reversible tyrosine kinase inhibitor KD019.
By Bernadette Toner
By a GenomeWeb staff reporter
By Molika Ashford
Originally published Feb. 20.
Mitomics said this week that it has signed a non-exclusive agreement with LabMD to market its Prostate Core Mitomic Test in the US.
By Turna Ray
Roche said this week that its Cobas CT/NG test for Chlamydia trachomatis and Neisseria gonorrhoeae infections has received 510(k) clearance from the US Food and Drug Administration.
By Turna Ray
Ventana Medical Systems has been in a deal-making frenzy around companion diagnostics development.
In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.
British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.
An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.
The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.